US FDA grants orphan drug designation to Privo Technologies cisplatin to treat CIS of anterior 2/3 of oral cavity

Privo Technologies, Inc. announced today that the US Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Privo